The content on this site is intended for healthcare professionals only
Prof Caldas presents at the symposium, 'Translational and tailored, but can we afford it?', at the 22nd European Association for Cancer Research, Barcelona, 8th July 2012.
The official EACR-22 sponsored satellite symposium was hosted by ecancer, in partnership with EurocanPlatform and Vall d’Hebron Institute of Oncology.
Download the slides here.
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Loco-regional management after neoadjuvant chemotherapy
Management of HER2 positive metastatic breast cancer treatment algorithm
